FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2317505050> ?p ?o ?g. }

• W2317505050 abstract "Immune checkpoint antagonists to PD-1/PD-L1 and immunostimulating cytokines such as IL-15 have shown success to some extent in certain clinical settings across multiple cancer types. However, the full potential of the checkpoint inhibitor is limited due to impaired overall antitumor immunity, and cytokine as single agent has insufficient half-life and systemic toxicities due to the lack of target specificity. To overcome these challenging hurdles, we developed a bifunctional fusion protein, KD-033, composed of an antibody specific for PD-L1 and complex of IL-15Rα sushi domain/IL-15 as a novel immunotherapeutic agent for achieving better antitumor efficacy. Previously, we presented the generation and characteristics of a prototype of bifunctional fusion protein and its potential of in vivo antitumor activity. Here, we report a genetically modified fusion protein that has enhanced immunological activity and capability to achieve stronger antitumor efficacy in tumor models in comparison with either single agent. Our data indicate that the improved bifunctional fusion protein has favorable thermal stability and can be efficiently expressed in mammalian cells. The bifunctional fusion protein has higher affinity to PD-L1, silenced binding activity to Fc receptors and better ability to increase the secretion of Th1 cytokine, i.e. gamma IFN and the cytotoxicity of CD8 T-cells and NK cells to tumor cells as assessed in immunological assays. In preclinical study, KD033 had stronger anti-tumor efficacy in controlling primary tumor growth and prolonging the survival of tumor bearing mice in a number of mouse tumor models including those aggressive tumor models. Furthermore, the PD-L1 targeted bifunctional protein had significantly less cytokine-related toxicity when compared to non-targeted full IgG/IL-15Rα sushi domain/IL-15 fusion protein in vivo. These results demonstrate that KD033 has the capacity of targeting IL-15-stimulated innate and adaptive immune effectors into local tumor sites, thereby effectively controlling tumor progression while having minimized potential adverse effect in vivo. The preclinical studies of the novel immunotherapeutics warrant further investigation towards the clinical development of the bifunctional immunotherapeutic agent for cancer treatment. Citation Format: Yan Wu, Zhaojing Zhong, Stella Martomo, Dan Lu, Zhanna Polonskaya, Xenia Luna, Haifan Zhang, Zhikai Zhang, Zhun Wang, Leo Liu, Jeegar Patel, James Tonra, Henry Li, Larry Witte, Sam Waksal, Zhenping Zhu. Anti-PD-L1 antibody-based IL-15 immunocytokine has enhanced antitumor immunity. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr C173." @default.
• W2317505050 created "2016-06-24" @default.
• W2317505050 creator A5002815845 @default.
• W2317505050 creator A5009923185 @default.
• W2317505050 creator A5011356818 @default.
• W2317505050 creator A5011946503 @default.
• W2317505050 creator A5021623952 @default.
• W2317505050 creator A5023830968 @default.
• W2317505050 creator A5030014755 @default.
• W2317505050 creator A5032275255 @default.
• W2317505050 creator A5037546003 @default.
• W2317505050 creator A5044585969 @default.
• W2317505050 creator A5057661854 @default.
• W2317505050 creator A5064950120 @default.
• W2317505050 creator A5069756943 @default.
• W2317505050 creator A5075372173 @default.
• W2317505050 creator A5088260595 @default.
• W2317505050 creator A5088552348 @default.
• W2317505050 date "2015-12-01" @default.
• W2317505050 modified "2023-09-25" @default.
• W2317505050 title "Abstract C173: Anti-PD-L1 antibody-based IL-15 immunocytokine has enhanced antitumor immunity" @default.
• W2317505050 doi "https://doi.org/10.1158/1535-7163.targ-15-c173" @default.
• W2317505050 hasPublicationYear "2015" @default.
• W2317505050 type Work @default.
• W2317505050 sameAs 2317505050 @default.
• W2317505050 citedByCount "1" @default.
• W2317505050 countsByYear W23175050502017 @default.
• W2317505050 crossrefType "proceedings-article" @default.
• W2317505050 hasAuthorship W2317505050A5002815845 @default.
• W2317505050 hasAuthorship W2317505050A5009923185 @default.
• W2317505050 hasAuthorship W2317505050A5011356818 @default.
• W2317505050 hasAuthorship W2317505050A5011946503 @default.
• W2317505050 hasAuthorship W2317505050A5021623952 @default.
• W2317505050 hasAuthorship W2317505050A5023830968 @default.
• W2317505050 hasAuthorship W2317505050A5030014755 @default.
• W2317505050 hasAuthorship W2317505050A5032275255 @default.
• W2317505050 hasAuthorship W2317505050A5037546003 @default.
• W2317505050 hasAuthorship W2317505050A5044585969 @default.
• W2317505050 hasAuthorship W2317505050A5057661854 @default.
• W2317505050 hasAuthorship W2317505050A5064950120 @default.
• W2317505050 hasAuthorship W2317505050A5069756943 @default.
• W2317505050 hasAuthorship W2317505050A5075372173 @default.
• W2317505050 hasAuthorship W2317505050A5088260595 @default.
• W2317505050 hasAuthorship W2317505050A5088552348 @default.
• W2317505050 hasConcept C104317684 @default.
• W2317505050 hasConcept C123894998 @default.
• W2317505050 hasConcept C159654299 @default.
• W2317505050 hasConcept C167672396 @default.
• W2317505050 hasConcept C203014093 @default.
• W2317505050 hasConcept C2777701055 @default.
• W2317505050 hasConcept C2778690821 @default.
• W2317505050 hasConcept C2779341262 @default.
• W2317505050 hasConcept C2780674031 @default.
• W2317505050 hasConcept C40767141 @default.
• W2317505050 hasConcept C502942594 @default.
• W2317505050 hasConcept C55493867 @default.
• W2317505050 hasConcept C86803240 @default.
• W2317505050 hasConcept C8891405 @default.
• W2317505050 hasConceptScore W2317505050C104317684 @default.
• W2317505050 hasConceptScore W2317505050C123894998 @default.
• W2317505050 hasConceptScore W2317505050C159654299 @default.
• W2317505050 hasConceptScore W2317505050C167672396 @default.
• W2317505050 hasConceptScore W2317505050C203014093 @default.
• W2317505050 hasConceptScore W2317505050C2777701055 @default.
• W2317505050 hasConceptScore W2317505050C2778690821 @default.
• W2317505050 hasConceptScore W2317505050C2779341262 @default.
• W2317505050 hasConceptScore W2317505050C2780674031 @default.
• W2317505050 hasConceptScore W2317505050C40767141 @default.
• W2317505050 hasConceptScore W2317505050C502942594 @default.
• W2317505050 hasConceptScore W2317505050C55493867 @default.
• W2317505050 hasConceptScore W2317505050C86803240 @default.
• W2317505050 hasConceptScore W2317505050C8891405 @default.
• W2317505050 hasLocation W23175050501 @default.
• W2317505050 hasOpenAccess W2317505050 @default.
• W2317505050 hasPrimaryLocation W23175050501 @default.
• W2317505050 hasRelatedWork W1269684 @default.
• W2317505050 hasRelatedWork W13860227 @default.
• W2317505050 hasRelatedWork W16473764 @default.
• W2317505050 hasRelatedWork W19172956 @default.
• W2317505050 hasRelatedWork W2151330 @default.
• W2317505050 hasRelatedWork W23919685 @default.
• W2317505050 hasRelatedWork W25833474 @default.
• W2317505050 hasRelatedWork W29670928 @default.
• W2317505050 hasRelatedWork W35513613 @default.
• W2317505050 hasRelatedWork W6417289 @default.
• W2317505050 isParatext "false" @default.
• W2317505050 isRetracted "false" @default.
• W2317505050 magId "2317505050" @default.
• W2317505050 workType "article" @default.